Insurance approval delays could affect treatment of juvenile idiopathic arthritis

• Posted on: Jun 14 2022
• By: Saratoga Opthalmology
• Leave a response

Tumor necrosis factor inhibitors are increasingly being used to treat juvenile idiopathic arthritis, but delays in treatment authorization could lead to negative effects.
Source: AAO

Posted in: Uncategorized